Content
Search
Navigation
Sitemap
About us
About us
Who we are
Our model
The Syncona platform
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
Gyroscope Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Previous investments
Overview
Blue Earth
Nightstar
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chief Executive, SIML
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Aligning with UN SDGs
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment case
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Sustainability
Sustainability policies
17.06.21
Approach to Taxation
PDF (0.12Mb)
17.06.21
Climate ambition statement
PDF (0.09Mb)
17.06.21
Modern Slavery Statement
PDF (0.16Mb)
17.06.21
Responsible Investment Policy
PDF (0.13Mb)
17.06.21
Sustainability Policy
PDF (0.27Mb)
Close menu
About us
About us
Who we are
Our model
The Syncona platform
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
Gyroscope Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Previous investments
Overview
Blue Earth
Nightstar
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chief Executive, SIML
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Aligning with UN SDGs
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment case
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search